Press Releases

Date	Title	File/s
Aug 11, 2026	Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 07, 2026	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Aug 04, 2026	Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
Aug 03, 2026	Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
Jun 25, 2026	Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
Jun 24, 2026	Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Jun 24, 2026	Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Jun 22, 2026	Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
Jun 05, 2026	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 06, 2026	Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update